Merck Collaborates with Foghorn to Develop Oncology Therapies Against Transcription Factor Target

 Merck Collaborates with Foghorn to Develop Oncology Therapies Against Transcription Factor Target

Merck Collaborates with Foghorn to Develop Oncology Therapies Against Transcription Factor Target

Shots:

  • Foghorn will receive an upfront, development, regulatory and commercial milestones totaling up to $425M as well as royalties on sales of any approved therapy emerges from the collaboration
  • Merck to get an exclusive global right to develop and commercialize drugs targeting dysregulation of a single transcription factor. The collaboration will deploy Foghorn’s Gene Traffic Control platform to discover and develop novel therapies against a transcription factor target
  • Utilizing its Gene Traffic Control platform, Foghorn is interrogating and drugging the chromatin regulatory system. The company is advancing ~10 small molecule and protein degrader programs across multiple cancer indications and expects to file an IND for its first program in H2’20

Click here to read full press release/ article | Ref: PRNewswire | Image: The Conversion

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post